Fusion Antibodies PLC Director/PDMR Shareholding (0499A)
September 24 2020 - 8:39AM
UK Regulatory
TIDMFAB
RNS Number : 0499A
Fusion Antibodies PLC
24 September 2020
Fusion Antibodies plc
("Fusion" or the "Company")
Director/PDMR Shareholding
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, has been notified that on 23
September 2020, Alan Mawson, Non-Executive Director, sold 20,000
ordinary shares in the Company ("Ordinary Shares") from his pension
fund at a price of 180 pence per Ordinary Share.
Following this sale, Alan Mawson has a direct and indirect
interest in 124,000 Ordinary Shares, representing approximately
0.49 per cent. of the Company's issued share capital. Alan Mawson
is also a Non-Executive Director of Clarendon Fund Managers Limited
("Clarendon") and sits on Clarendon's investment committee.
Clarendon is the fund manager for Nitech Growth Fund LP which holds
358,850 Ordinary Shares and Viridian Growth Fund LP which holds
1,831,500 Ordinary Shares.
The following notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
details.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Alan Mawson
-------------------------- ----------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------- ----------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name Fusion Antibodies plc
-------------------------- ----------------------------------------------
b) LEI 213800KBAYRC9VOQ9V39
-------------------------- ----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------
a) Description of the Ordinary shares of 4p each in Fusion
financial instrument, Antibodies plc
type of instrument Identification code (ISIN) for Fusion
Identification code Antibodies plc ordinary shares: GB00BDQZGK16
-------------------------- ----------------------------------------------
b) Nature of the transaction Sale of shares
-------------------------- ----------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
180p 20,000
----------
-------------------------- ----------------------------------------------
d) Aggregated information: N/A
- Aggregated volume
- Price
-------------------------- ----------------------------------------------
e) Date of the transaction 23 September 2020
-------------------------- ----------------------------------------------
f) Place of the transaction London Stock Exchange, XLON
-------------------------- ----------------------------------------------
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Asha Chotai (Corporate
Finance)
Tony Quirke (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx (TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 100 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. The Company's mission is to enable
pharmaceutical and diagnostic companies to develop innovative
products in a timely and cost-effective manner for the benefit of
the global healthcare industry. Fusion Antibodies provides a broad
range of services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotechs get to the
clinic faster, with the optimal drug candidate and ultimately speed
up the drug development process.
The global monoclonal antibody therapeutics market was valued at
$135.4 billion in 2018 and is forecast to surpass $212.6 billion in
2022, an increase at a CAGR of 12.0 per cent. for the period 2018
to 2022. In 2017, seven of the world's ten top selling drugs were
antibody-based therapeutics with the combined annual sales of these
drugs exceeding $63.2 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSEAFDLESSEDU
(END) Dow Jones Newswires
September 24, 2020 09:39 ET (13:39 GMT)
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2023 to Apr 2024